Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II neoadjuvant subtype-directed treatment study in HER2-negative breast cancer
2006-004510-41Phase 2Active
- Sponsor
- GEICAM
- Start
- Mar 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, epirubicin, cyclophosphamide, goserelin, exemestane and 1 more in breast cancer (2 arms), sponsored by GEICAM. Primary endpoints: Efficacy of treatment, Clinical response rate before surgery by MRI in luminal A subtype and 2 more. Started Mar 2010; status: active.
02
Drugs
docetaxelepirubicincyclophosphamidegoserelinexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004510-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004510-41.